The UK company is investing £3 million in new instrumentation and equipment to strengthen its high-throughput screening and translational oncology service offerings.
Sygnature Discovery is investing £3 million in new instrumentation and equipment to strengthen its high-throughput screening (HTS) and translational oncology service offerings. Part of the investment will be used to establish internal flow cytometry support for ex-vivo tumor analysis, the company disclosed in a press release dated Dec. 16. Sygnature had added HTS capabilities to its range of identification solutions in November 2019.
“Despite the challenges brought about by the COVID-19 pandemic during 2020, Sygnature Discovery has continued to deliver top quality science to accelerate customers’ drug discovery programmes,” Sygnature CEO and founder, Dr. Simon Hirst, commented in a press release issued on Dec. 16, 2020. “This considerable funding injection will enable Sygnature to provide an even more comprehensive integrated service offering, from hit identification to pre-clinical candidate selection. We have reached an exciting point in our company’s 16-year history, and 2021 will undoubtedly bring even more exciting developments for our business,” he said in the release.
Source: Sygnature Discovery
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.